Cover

Antiplatelet Therapy in ACS and A-Fib

Editor(s): Serebruany V.L. (Towson, Md.) 
Atar D. (Oslo) 
Table of Contents
Vol. 47, 2012
Section title: Paper
Serebruany VL, Atar D (eds): Antiplatelet Therapy in ACS and A-Fib. Adv Cardiol. Basel, Karger, 2012, vol 47, pp 5–19
(DOI:10.1159/000338060)

Impact of Antiplatelet Therapy in Heart Disease

Renda G. · de Caterina R.
Institute of Cardiology and Center of Excellence on Aging, ‘G. d’Annunzio’ University, Chieti, Italy

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 33.00
Account: USD 23.00

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 8/9/2012
Cover Date: 2012

Number of Print Pages: 15
Number of Figures: 2
Number of Tables: 2

ISBN: 978-3-318-02168-4 (Print)
eISBN: 978-3-318-02169-1 (Online)

Abstract

Because platelet activation plays an important pathophysiological role in acute coronary syndromes, antiplatelet agents are a mainstay of cardiovascular therapy, both in high-risk primary prevention and in secondary prevention. This is usually done with aspirin in all such cases, and adding a P2Y12 inhibitor in secondary prevention usually for 1 year after an acute coronary syndrome, especially after stent implantation. P2Y12 inhibitors include ticlopidine (now rarely used), clopidogrel, prasugrel, and ticagrelor. In the setting of high-risk acute coronary syndromes treated with percutaneous coronary interventions, the addition of a glycoprotein IIb/IIIa antagonist, especially abciximab, is contemplated. Conversely, the role of antiplatelet therapy in preventing stroke after atrial fibrillation has been recently downgraded in most risk classes, in favor of anticoagulants. This chapter provides a general overview of the use of antiplatelet agents in heart disease.


  

Author Contacts

Raffaele de Caterina, MD, PhD, FESC, Institute of Cardiology, ‘G. d’Annunzio’ University, Chieti, C/o Ospedale SS. Annunziata, Via dei Vestini, IT–66013 Chieti (Italy), Tel. +39 0871 41512, E-Mail rdecater@unich.it

  

Article Information

Published online: August 09, 2012
Number of Print Pages : 15

  

Publication Details

Book Serie: Advances in Cardiology, Vol. 47, Year 2012

Editor(s): Borer, J.S. (New York, N.Y.)
ISSN: 0065-2326 (Print), eISSN: 1662-2839 (Online)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=0065-2326

Book Title: Antiplatelet Therapy in ACS and A-Fib

Editor(s): Serebruany VL, Atar D (eds)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=0065-2326&volume=47


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 8/9/2012
Cover Date: 2012

Number of Print Pages: 15
Number of Figures: 2
Number of Tables: 2

ISBN: 978-3-318-02168-4 (Print)
eISBN: 978-3-318-02169-1 (Online)


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.